Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL613107 Target Snapshot

PBMC · CELL-LINE · Homo sapiens

5,308Compounds
1,765Assays
44Approved Drugs
4,026.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Confirm a stable target identifier before relying on this context across project surfaces.

Review focus
Open DB context pending

Confirm a stable target identifier before relying on this context across project surfaces.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats PBMC as ChEMBL target CHEMBL613107. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
PBMC
CELL-LINE · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL613107
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether PBMC still has a stable protein naming contract across sources.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelPBMC
UniProt AccessionN/A

PBMC

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as PBMC.

Review namePBMC
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

44
Approved
8
Phase III
19
Phase II
3
Phase I
Assay Mix

Activity Type Distribution

IC503,652.0
EC50374.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL570015 11.0 IC50 0.01 Clinical
CHEMBL475397 10.92 IC50 0.012 Preclinical
CHEMBL516398 10.85 IC50 0.014 Preclinical
CHEMBL514182 10.8 IC50 0.016 Preclinical
CHEMBL3288029 10.7 IC50 0.01995 Preclinical
CHEMBL193240 10.7 IC50 0.02 Approved
CHEMBL492749 10.6 IC50 0.025 Preclinical
CHEMBL492522 10.6 IC50 0.025 Preclinical
CHEMBL846 10.54 IC50 0.029 Approved
CHEMBL1834544 10.52 IC50 0.03 Preclinical
Distribution

pChEMBL Value Distribution

312
5.0
325
5.5
347
6.0
311
6.5
252
7.0
162
7.5
113
8.0
67
8.5
45
9.0
20
9.5
pChEMBL
Approved Drugs

Approved Drugs

GIVINOSTAT
CHEMBL1213492
Approved 2024
CRISABOROLE
CHEMBL484785
Approved 2016
APREMILAST
CHEMBL514800
Approved 2014
POMALIDOMIDE
CHEMBL43452
Approved 2013
TOFACITINIB
CHEMBL221959
Approved 2012
RUXOLITINIB
CHEMBL1789941
Approved 2011
ROFLUMILAST
CHEMBL193240
Approved 2010
PLERIXAFOR
CHEMBL18442
Approved 2008
FLUTICASONE FUROATE
CHEMBL1676
Approved 2007
VORINOSTAT
CHEMBL98
Approved 2006
LENALIDOMIDE
CHEMBL848
Approved 2005
MYCOPHENOLIC ACID
CHEMBL866
Approved 2004
NEVIRAPINE
CHEMBL57
Approved 1996
LAMIVUDINE
CHEMBL141
Approved 1995
TACROLIMUS ANHYDROUS
CHEMBL269732
Approved 1994
BUDESONIDE
CHEMBL1370
Approved 1994
FLUTICASONE PROPIONATE
CHEMBL1473
Approved 1990
ZIDOVUDINE
CHEMBL129
Approved 1987
CYCLOSPORINE
CHEMBL160
Approved 1983
CALCITRIOL
CHEMBL846
Approved 1978
DOXORUBICIN
CHEMBL53463
Approved 1974
AZATHIOPRINE
CHEMBL1542
Approved 1968
DEXAMETHASONE
CHEMBL384467
Approved 1958
MERCAPTOPURINE ANHYDROUS
CHEMBL1425
Approved 1953
Assay Landscape

Assay Landscape

1,765
Total Assays
1,608
Tested Compounds
4
Assay Types
Functional — 1,040 assays, 1,608 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 1,038 1,608 6.6
organism-based format 2 0
ADME — 666 assays, 538 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 647 538 5.0
organism-based format 19 0
Toxicity — 51 assays, 11 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 51 11 5.7
Unassigned — 8 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 8 0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine